ArticleJCI insight2018

TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti-PD-1/anti-CTLA-4 immunotherapy.

Heng-Jia Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.